Identification of a novel BET bromodomain inhibitor‐sensitive, gene regulatory circuit that controls Rituximab response and tumour growth in aggressive lymphoid cancers

Identification of a novel BET bromodomain inhibitor‐sensitive, gene regulatory circuit that controls Rituximab response and tumour growth in aggressive lymphoid cancers

Abstract Immuno‐chemotherapy elicit high response rates in B‐cell non‐Hodgkin lymphoma but heterogeneity in response duration is observed, with some patients achieving cure and others showing refractory disease or relapse. Using a transcriptome‐powered targeted proteomics screen, we discovered a gen...

Full description

Bibliographic Details
Main Authors: Anouk Emadali, Sophie Rousseaux, Juliana Bruder‐Costa, Claire Rome, Samuel Duley, Sieme Hamaidia, Patricia Betton, Alexandra Debernardi, Dominique Leroux, Benoit Bernay, Sylvie Kieffer‐Jaquinod, Florence Combes, Elena Ferri, Charles E. McKenna, Carlo Petosa, Christophe Bruley, Jérôme Garin, Myriam Ferro, Rémy Gressin, Mary B. Callanan, Saadi Khochbin
Format: Article
Language:English
Published: Springer Nature 2013-07-01
Series:EMBO Molecular Medicine
Subjects:
cancer‐testis factor
CCDC86
CD40
double‐hit B‐cell non‐Hodgkin's lymphoma
R‐CHOP
Online Access:https://doi.org/10.1002/emmm.201202034

Internet

https://doi.org/10.1002/emmm.201202034

Similar Items